A Phase 2 interventional study of Bevacizumab (Avastin®) and Docetaxel (Taxotere®) in Ovarian Cancer, sponsored by Sanofi. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-23.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies testing bevacizumab in Ovarian Neoplasms — 22 open to participants now, 32 under way, 9 of them phase 3. Bevacizumab · Ovarian Neoplasms.
Among the 106 studies testing bevacizumab in Ovarian Neoplasms, this one is the 28th largest by enrollment, is one of 6 that started in 2006, is one of 66 in phase 2, and was the 8th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →22 of the 106 studies testing bevacizumab in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
CSPC Megalith Biopharmaceutical Co.,Ltd. · Sites in China
Ages 18+
Jiangsu Cancer Institute & Hospital · Sites in China
Ages 18–75
Medical University of South Carolina · Sites in United States
Ages 18+
Nanjing Leads Biolabs Co.,Ltd · Sites in China
Ages 18+
AbbVie · Sites in United States, Australia, Belgium and 5 more countries
Ages 18+ · Women only
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 73 · Phase 3 20 · Phase 4 2
First in 2003; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 52 across the 106 interventional studies. Of the 60 that completed or were terminated, 37 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 106 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
14 studies in Ovarian Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 14 studies in Ovarian Neoplasms by Sanofi, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2006, is one of 9 in phase 2, and was the 2nd registered.
Sanofi’s Ovarian Neoplasms studies by the year they started, since 1999.
7 of the studies testing bevacizumab in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT05636111M.D. Anderson Cancer CenterPhase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | 2026-12-31 |
| NCT02884648M.D. Anderson Cancer CenterBevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery | 2027-02-02 |
| NCT07453394Qilu Pharmaceutical Co., Ltd.QLS5132 Combination Therapy in Advanced Solid Tumors | 2027-04 |
| NCT06799065Accent TherapeuticsFirst-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 106 studies testing bevacizumab in Ovarian Neoplasms, from their registry updates:
Among Sanofi’s 14 in Ovarian Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis of ovarian cancer by concurrent addition of bevacizumab (Avastin®).
Participants were
Participants were followed for survival for a minimum 3 years from the date of enrollment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
Participants with serious, non-healing wound, ulcer, or bone fracture. This includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days.
Participants with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with International Federation of Gynecology and Obstetrics (FIGO) stage IB through IV ovarian, primary peritoneal, or fallopian tube carcinoma treated with Oxaliplatin, Docetaxel, and Bevacizumab - 28 days after initial surgery
Drug: Bevacizumab (Avastin®) · Drug: Docetaxel (Taxotere®) · Drug: Oxaliplatin (Eloxatin®)
15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
75 mg/m\^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
85 mg/m\^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
Twelve-month Progression-free Survival (PFS) Rate in Participants
Tumor assessments were performed by Computed tomography (CT) and Magnetic Resonance Imaging (MRI) to evaluate disease progression based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST). Disease progression was recorded as any one of the following: * appearance of a new lesion * symptomatic deterioration * progression of target or nontarget lesions * death Participants who did not die or show show disease progression achieved PFS. PFS rate is the percent of participants who achieved PFS.
Time frame: up to 12 months following treatment initiation
Twenty Four-month Progression-free Survival (PFS) Rate in Participants
Tumor assessments were performed by Computed tomography (CT) and Magnetic Resonance Imaging (MRI) to evaluate disease progression based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST). Disease progression was recorded as any one of the following: * appearance of a new lesion * symptomatic deterioration * progression of target or nontarget lesions * death Participants who did not die or show show disease progression achieved PFS. PFS rate is the percent of participants who achieved PFS.
Time frame: up to 24 months following treatment initiation
Median Time to Progression-free Survival (PFS)
Time to PFS was the interval from the date of registration to the earliest date of disease progression or death, whichever occurred first. Time of PFS was censored * on the last available tumor assessment date for participants leaving the study prior to disease progression or death; and also for participants requiring off-study medication or additional debulking surgery (where assessment date used was the one prior to off-study medication or surgery), * at Day 1, for living participants with no post-baseline tumor assessments. Median PFS was estimated from a Kaplan-Meier curve.
Time frame: up to approximately 1300 days following treatment initiation
Tumor Response Rate Based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST)
Tumors were assessed by CT and MRI. Tumor response was evaluated by GOG RECIST in which: * Complete response (CR) was the disappearance of all target and non-target lesions, with no evidence of new lesions * Partial response (PR) was at least a 30% decrease in the sum of longest dimensions (LD) of all measurable target lesions Participants with a response (CR or PR) were to have the initial response confirmed by tumor imaging in 4-6 weeks.
Time frame: up to 12 months following treatment initiation
Twelve-month Recurrence-free Survival (RFS) Rate in Participants With Non Measurable Disease at Baseline
Participants with Recurrence-free survival (RFS) were participants with a non-measurable disease at baseline, who had not achieved disease progression nor had died. Disease progression included the following: * the appearance of a new lesion * symptomatic deterioration * progression of non-target lesions * a predefined serum CA 125 increase. RFS rate was the percent of participants in the non-measurable disease subgroup who achieved RFS.
Time frame: up to 12 months following treatment initiation
Median Time to Recurrence-free Survival (RFS) in Participants With Non-measurable Disease at Baseline
The time to RFS was programmatically defined as the interval from the date of registration to the earliest date of disease progression or death, whichever occurred first. Participants were * censored on the last available CA 125 biomarker blood draw date if * left the study prior to disease progression or death * they received off-study anti-tumor medication * underwent debulking surgery * censored at Day 1 if they were alive had no post baseline CA 125 biomarker blood draw.
Time frame: up to approximately 1500 days following treatment initiation
CA-125 Response Rate
A CA-125 response was considered at least a 50% reduction in the level of the biomarker, CA-125, from a pretreatment level, which was confirmed and maintained for at least 28 days. The overall CA-125 biomarker response rate was defined as the number of participants in the measurable disease subgroup who met the above criteria at least once within the study treatment period +21 days, divided by the number of evaluable participants in the disease subgroup.
Time frame: up to 12 months after treatment initiation
Overall Survival Rate
Survival was the observed length of life from entry into the study to death or the date of last contact. The overall survival rate (percentage of participants showing survival) at 12 and 24-months is reported here.
Time frame: up to up to approximately 1700 days after treatment initiation
Median Overall Survival Time
Survival was the observed length of life from entry into the study to death or the date of last contact. The median overall survival time was estimated using Kaplan-Meier Curve.
Time frame: up to approximately 1700 days after treatment initiation
152 participants were screened for the study. 20 were screen failures. 132 participants met eligibity criteria and were treated with study medication.
| Milestone | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| Started | 132 |
| Completed | 58 |
| Not completed | 74 |
| Withdrew: Disease progression | 37 |
| Withdrew: Adverse event | 18 |
| Withdrew: Investigator/participant request | 5 |
| Withdrew: Non-compliance | 1 |
| Withdrew: Missing for end of treatment | 4 |
| Withdrew: Progression based on ca-125 (biomarker) | 2 |
| Withdrew: Poor performance status | 1 |
| Withdrew: Relocation to florida | 1 |
| Withdrew: Noncompliance/decision to discontinue | 1 |
| Withdrew: Urine protein/creatinine ratio delay | 1 |
| Withdrew: Neuropathy/patient preference | 1 |
| Withdrew: Proteinuria | 1 |
| Withdrew: Ineligibility due to radiation treatment | 1 |
Tumor assessments were performed by Computed tomography (CT) and Magnetic Resonance Imaging (MRI) to evaluate disease progression based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST). Disease progression was recorded as any one of the following: * appearance of a new lesion * symptomatic deterioration * progression of target or nontarget lesions * death Participants who did not die or show show disease progression achieved PFS. PFS rate is the percent of participants who achieved PFS.
| percentage of participants | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| Twelve-month Progression-free Survival (PFS) Rate in Participants | 65.7 (53.4 to 76.7) |
Tumor assessments were performed by Computed tomography (CT) and Magnetic Resonance Imaging (MRI) to evaluate disease progression based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST). Disease progression was recorded as any one of the following: * appearance of a new lesion * symptomatic deterioration * progression of target or nontarget lesions * death Participants who did not die or show show disease progression achieved PFS. PFS rate is the percent of participants who achieved PFS.
| percentage of participants | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| Twenty Four-month Progression-free Survival (PFS) Rate in Participants | 34.3 (23.3 to 46.6) |
Time to PFS was the interval from the date of registration to the earliest date of disease progression or death, whichever occurred first. Time of PFS was censored * on the last available tumor assessment date for participants leaving the study prior to disease progression or death; and also for participants requiring off-study medication or additional debulking surgery (where assessment date used was the one prior to off-study medication or surgery), * at Day 1, for living participants with no post-baseline tumor assessments. Median PFS was estimated from a Kaplan-Meier curve.
| days | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| Median Time to Progression-free Survival (PFS) | 495 (384 to 596) |
Tumors were assessed by CT and MRI. Tumor response was evaluated by GOG RECIST in which: * Complete response (CR) was the disappearance of all target and non-target lesions, with no evidence of new lesions * Partial response (PR) was at least a 30% decrease in the sum of longest dimensions (LD) of all measurable target lesions Participants with a response (CR or PR) were to have the initial response confirmed by tumor imaging in 4-6 weeks.
| participants | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| Unconfirmed response (CR+PR) | 51 |
| Unconfirmed complete response (CR) | 23 |
| Unconfirmed partial response (PR) | 28 |
| Unconfirmed progressive disease (PD) | 5 |
| Confirmed response (CR+PR) | 41 |
| Confirmed complete response (CR) | 21 |
| Confirmed partial response (PR) | 20 |
Participants with Recurrence-free survival (RFS) were participants with a non-measurable disease at baseline, who had not achieved disease progression nor had died. Disease progression included the following: * the appearance of a new lesion * symptomatic deterioration * progression of non-target lesions * a predefined serum CA 125 increase. RFS rate was the percent of participants in the non-measurable disease subgroup who achieved RFS.
| percentage of participants | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| Twelve-month Recurrence-free Survival (RFS) Rate in Participants With Non Measurable Disease at Baseline | 67.5 (50.9 to 81.4) |
The time to RFS was programmatically defined as the interval from the date of registration to the earliest date of disease progression or death, whichever occurred first. Participants were * censored on the last available CA 125 biomarker blood draw date if * left the study prior to disease progression or death * they received off-study anti-tumor medication * underwent debulking surgery * censored at Day 1 if they were alive had no post baseline CA 125 biomarker blood draw.
| days | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| Median Time to Recurrence-free Survival (RFS) in Participants With Non-measurable Disease at Baseline | 631 (427 to NA) |
A CA-125 response was considered at least a 50% reduction in the level of the biomarker, CA-125, from a pretreatment level, which was confirmed and maintained for at least 28 days. The overall CA-125 biomarker response rate was defined as the number of participants in the measurable disease subgroup who met the above criteria at least once within the study treatment period +21 days, divided by the number of evaluable participants in the disease subgroup.
| percentage of participants | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| With non-measurable disease at baseline (N=27) | 81.5 (61.9 to 93.7) |
| With measurable disease at baseline (N=53) | 83.0 (70.2 to 91.9) |
Survival was the observed length of life from entry into the study to death or the date of last contact. The overall survival rate (percentage of participants showing survival) at 12 and 24-months is reported here.
| percentage of participants | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| Overall survival at 12 months | 85.5 (77.5 to 91.5) |
| Overall survival at 24 months | 71.8 (62.4 to 80.0) |
Survival was the observed length of life from entry into the study to death or the date of last contact. The median overall survival time was estimated using Kaplan-Meier Curve.
| days | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| Median Overall Survival Time | 1437.0 (1036.0 to NA) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oxaliplatin/Docetaxel/Bevacizumab | — | 33/132 (25%) | 130/132 (98.5%) |
| Event | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| NauseaGastrointestinal disorders | 7/132 |
| VomitingGastrointestinal disorders | 7/132 |
| Small intestinal obstructionGastrointestinal disorders | 5/132 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/132 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/132 |
| Abdominal painGastrointestinal disorders | 3/132 |
| DehydrationMetabolism and nutrition disorders | 3/132 |
| NeutropeniaBlood and lymphatic system disorders | 1/132 |
| Cardiac failure congestiveCardiac disorders | 1/132 |
| Supraventricular tachycardiaCardiac disorders | 1/132 |
| Event | Oxaliplatin/Docetaxel/Bevacizumab |
|---|---|
| FatigueGeneral disorders | 101/132 |
| AlopeciaSkin and subcutaneous tissue disorders | 86/132 |
| NauseaGastrointestinal disorders | 85/132 |
| DiarrhoeaGastrointestinal disorders | 77/132 |
| Neuropathy peripheralNervous system disorders | 64/132 |
| NeutropeniaBlood and lymphatic system disorders | 59/132 |
| ConstipationGastrointestinal disorders | 59/132 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 47/132 |
| Decreased appetiteMetabolism and nutrition disorders | 44/132 |
| VomitingGastrointestinal disorders | 42/132 |
| Age Continuous(years) | Oxaliplatin/Docetaxel/Bevacizumab (Measurable Disease) | Oxaliplatin/Docetaxel/Bevacizumab (Non-Measurable Disease) | Total |
|---|---|---|---|
| Mean | 57.5 ± 10.43 | 60.9 ± 9.54 | 58.8 ± 10.19 |
| Sex: Female, Male(Participants) | Oxaliplatin/Docetaxel/Bevacizumab (Measurable Disease) | Oxaliplatin/Docetaxel/Bevacizumab (Non-Measurable Disease) | Total |
|---|---|---|---|
| Female | 80 | 52 | 132 |
| Male | 0 | 0 | 0 |
| Primary Tumor Site(participants) | Oxaliplatin/Docetaxel/Bevacizumab (Measurable Disease) | Oxaliplatin/Docetaxel/Bevacizumab (Non-Measurable Disease) | Total |
|---|---|---|---|
| Ovary | 65 | 45 | 110 |
| Fallopian tube | 6 | 5 | 11 |
| Peritoneum | 9 | 2 | 11 |
| FIGO stage at diagnosis(participants) | Oxaliplatin/Docetaxel/Bevacizumab (Measurable Disease) | Oxaliplatin/Docetaxel/Bevacizumab (Non-Measurable Disease) | Total |
|---|---|---|---|
| Stage IB | 0 | 0 | 0 |
| Stage IC | 0 | 3 | 3 |
| Stage IIA | 0 | 0 | 0 |
| Stage IIB | 0 | 0 | 0 |
| Stage IIC | 3 | 5 | 8 |
| Stage IIIA | 3 | 2 | 5 |
| Stage IIIB | 2 | 5 | 7 |
| Stage IIIC | 57 | 32 | 89 |
| Stage IV | 15 | 5 | 20 |
The record gives a start of Mar 2006, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Docetaxel · Oxaliplatin